Search hospitals
>
Alberta
>
EDMONTON
Cross Cancer Institute
Claim this profile
EDMONTON, Alberta T6G 1Z2
Global Leader in Lung Cancer
Global Leader in Cancer
Conducts research for Breast Cancer
Conducts research for Prostate Cancer
Conducts research for Pancreatic Cancer
739 reported clinical trials
37 medical researchers
Summary
Cross Cancer Institute is a medical facility located in EDMONTON, Alberta. This center is recognized for care of Lung Cancer, Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer and other specialties. Cross Cancer Institute is involved with conducting 739 clinical trials across 462 conditions. There are 37 research doctors associated with this hospital, such as Quincy Chu, Michael Chu, MD, Michael Kolinsky, and Samir I. Patel.
Area of expertise
Lung Cancer
Cross Cancer Institute has run 113 trials for Lung Cancer. Some of their research focus areas include:
Cancer
Cross Cancer Institute has run 103 trials for Cancer. Some of their research focus areas include:
Top PIs
Quincy Chu
Cross Cancer Institute
9 years of reported clinical research
Michael Chu, MD
London Health Sciences Centre
4 years of reported clinical research
Michael Kolinsky
Cross Cancer Institute
4 years of reported clinical research
Samir I. Patel
Cross Cancer Institute
4 years of reported clinical research
Clinical Trials running at Cross Cancer Institute
Lung Cancer
Breast Cancer
Cancer
Bladder Cancer
Multiple Myeloma
Prostate Cancer
Pancreatic Cancer
Solid Tumors
Ovarian Cancer
Chronic Lymphocytic Leukemia
Telisotuzumab Vedotin vs. Docetaxel
for Non-Small Cell Lung Cancer
This trial is testing a new drug called telisotuzumab vedotin to see if it can treat a specific type of lung cancer better than an existing drug. The study focuses on adults whose lung cancer has not responded to previous treatments. The new drug targets and kills cancer cells by attaching to a specific protein on their surface.
Recruiting
2 awards
Phase 3
12 criteria
Sacituzumab Tirumotecan vs Standard Therapy
for Lung Cancer
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs). The primary hypotheses of this study are that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to progression-free survival (PFS) and overall survival (OS).
Recruiting
2 awards
Phase 3
2 criteria
Zongertinib
for Lung Cancer
This study is open to adults 18 years and older who have early-stage non-small cell lung cancer (NSCLC). Their cancer must have a specific change in a gene called HER2. Genes provide the instructions for making proteins, and this change leads to a faulty HER2 protein. People can join if their lung cancer was removed by surgery, and they have already received certain other anti-cancer treatments. The purpose of this study is to find out if a study medicine called zongertinib helps people with this type of cancer live longer without their cancer coming back after surgery, when compared to standard treatment. Zongertinib is being developed to target the faulty HER2 protein, which can cause cancer cells to grow. In this study, participants are assigned by chance to one of two treatment groups, with an equal chance of being in either group. One group takes the study medicine, zongertinib, by mouth once a day for up to 3 years. The other group receives a standard treatment, chosen by their doctor. This standard treatment may be an immunotherapy medicine given by infusion into a vein every 3 or 4 weeks for up to 1 year, or regular check-ups without active study medicine (observation). Participants can be in this study for up to about 11 years. During this time, they visit the study site regularly for check-ups and study-related tests. The frequency of these visits varies depending on their treatment and how long they have been in the study. In addition to visits at the study site, participants in some treatment groups will also have phone calls with the study team every 3 weeks to check on their health between their scheduled visits. Doctors check for any signs of cancer coming back using imaging scans (like CT or MRI scans); these scans are generally done every 3 months for the first 2 years, then every 6 months for the next 3 years, and then yearly. Participants also fill in questionnaires about their overall wellbeing, health and symptoms. Throughout the study, doctors also check participants' health and note any unwanted effects.
Recruiting
2 awards
Phase 3
6 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Cross Cancer Institute?
Cross Cancer Institute is a medical facility located in EDMONTON, Alberta. This center is recognized for care of Lung Cancer, Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer and other specialties. Cross Cancer Institute is involved with conducting 739 clinical trials across 462 conditions. There are 37 research doctors associated with this hospital, such as Quincy Chu, Michael Chu, MD, Michael Kolinsky, and Samir I. Patel.
Where is Cross Cancer Institute located?
The Cross Cancer Institute is situated at 11560 University Avenue NW, Edmonton, Alberta, T6G 1Z2. It is accessible by car, with real-time driving directions available to account for traffic and road conditions. For those preferring public transportation, bus and light rail stations are located at 117 Street & University Avenue and 114 Street & 83 Avenue.
Who should I call to ask about financial aid or insurance network?
**Cross Cancer Institute Financial Assistance and Insurance Information:** - **Memorial Sloan Kettering Cancer Center:** For insurance inquiries, contact 646-497-9176, Monday through Friday. - **Northwell Health:** Offers a financial assistance program for those uninsured or underinsured. Eligibility is based on family size and income, determined through an application process. - **Roswell Park Comprehensive Cancer Center:** Provides financial assistance for New York State residents who are uninsured or struggling with out-of-pocket costs. Contact financial counselors at 716-845-4782. - **NYU Langone Health:** Financial assistance available for patients without insurance or with partial insurance coverage. Apply through the financial assistance application and consult a financial counselor at any listed location.
What insurance does Cross Cancer Institute accept?
For information on insurance plans accepted by the Cross Cancer Institute in Alberta, Canada, please contact the institute directly.
What awards or recognition has Cross Cancer Institute received?
The Cross Cancer Institute, located in Edmonton, Alberta, is renowned for its comprehensive healthcare services for cancer patients. It has been awarded $5 million by the Alberta Cancer Foundation to fund innovative cancer research projects, underscoring its dedication to improving cancer care and treatment.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.